bpc-157 peptide pill vs injection FDA advisory committee votes to add popular to drug compounding list FDA scientists flag concerns with

The influence on the BPC-157 dopamine system, in particular, may explain some of the behavioral effects observed in animal studies, including antidepressant-like and anxiolytic-like activities

Side Effect Profiles TB-500 side effects: Head rush feeling post-injection (minutes) Temporary fatigue Increased hunger (some users) Hair growth (wanted or unwanted) Minimal serious concerns reported BPC-157 side effects: Essentially none reported commonly Theoretical cancer risk (unproven) Some report vivid dreams Rare headaches Both have excellent safety profiles in practice, though long-term data absent

What you need to know before using BPC157 & TB500 32 Do not use BPC157 & TB500 32 if you: Are allergic to either peptide or any excipients in the formulation Are pregnant or breastfeeding Are not trained in research handling or injection protocols Warnings and precautions: This product is not approved for therapeutic use and is intended for research purposes only Not for use in individuals under 18 years of age Speak to your research supervisor or healthcare provider if: You experience skin reactions at the injection site You have a bleeding disorder or are on anticoagulant therapy You are taking other peptide therapies Other substances and BPC157 & TB500: Avoid combining with other peptides or injectables unless part of a structured research protocol

Therefore, we hypothesized that BPC-157 is involved in the activation of MAPK signal pathway

That presents serious safety concerns of its own